Veradermics, Incorporated MANE 深 沪
等待开盘 04-30 09:30:00 美东时间
99.905
-3.195
-3.10%
华盛通- 最 高107.74
- 今 开104.82
- 成交量 38.09万股
- 最 低 98.015
- 昨 收 103.10
- 总市值 373.05万
- 52周最高 110.12
- 市盈率 静 --
- 换手率 1020.12%
- 52周最低 32.00
- 委 比 98.04%
- 总股本 3.73万
- 历史最高 110.12
- 量 比 0.48
- 振 幅 9.43%
- 历史最低 32.00
- 每 手 1
- 风险率 13.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 转型锂资源运输！海纳天成国际飙升近240%；X-Energy上市次日续涨超23%
转型锂资源运输！海纳天成国际飙升近240%；X-Energy上市次日续涨超23%，获亚马逊、ARK等明星机构支持>>
04-28 15:42
Veradermics announces launch of public offering
Veradermics (MANE) on Monday announced that it has launched a proposed public offering of 3.35M shares of common stock. All of the shares and pre-funded warrants are being offered by Veradermics. In a...
04-28 05:48
Veradermics Reports Phase 2/3 Data For VDPHL01; Shows Significant Hair Growth Gains (30-33 hairs/cm²) And Strong Efficacy Vs Placebo In Pattern Hair Loss Treatment
VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and
04-27 21:24
美股大行评级 | 巴克莱大幅上调希捷科技、西部数据目标价！联合健康、霍顿房屋、盈透证券、奎斯特诊疗等获多家机构上调目标价
今日重点评级关注：Piper Sandler：维持MeiraGTx Holdings"超配"评级，目标价从26美元升至30美元；康托·菲茨杰拉德：维持MKS Inc."超配"评级，目标价从300美元升至400美元
04-23 12:35
Leerink Partners Maintains Outperform on Veradermics, Raises Price Target to $90
Leerink Partners analyst Marc Goodman maintains Veradermics (NYSE:MANE) with a Outperform and raises the price target from $75 to $90.
04-22 22:09
Veradermics shares are trading lower. The company reported Q4 financial results.
Veradermics shares are trading lower. The company reported Q4 financial results.
03-30 22:59
Veradermics Q4 EPS $(0.62) Beats $(0.66) Estimate
Veradermics (NYSE:MANE) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.66) by 6.06 percent.
03-30 21:45
BRIEF-Veradermics Reports Fourth Quarter And Full Year 2025 Financial Results
BRIEF-Veradermics Reports Fourth Quarter And Full Year 2025 Financial Results March 30 (Reuters) - Veradermics Inc MANE.N : VERADERMICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CORPORATE AND CLINICAL UPDATES VERADERMICS INC - Q4 NET LOSS $21.8 MILLION Source
03-30 20:02
Veradermics FY25 net loss widens to $70 million; R&D expense climbs to $62 million
Veradermics FY25 net loss widens to $70 million; R&D expense climbs to $62 million Veradermics posted a Q4 net loss of $21.8 million, widening from a year earlier. Full-year net loss widened to $70 million. R&D expense jumped to $62.1 million, due to higher VDPHL01 clinical development spending and
03-30 19:31
Veradermics to present three VDPHL01 and hair-loss patient experience abstracts at AAD annual meeting
Veradermics to present three VDPHL01 and hair-loss patient experience abstracts at AAD annual meeting Veradermics said three abstracts will be presented at the American Academy of Dermatology Annual Meeting in Denver, Colorado, on March 27-31, 2026. Two social listening presentations are scheduled f
03-18 19:00
